32 withdrawn. 32 Phase 3, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 32 | Withdrawn 32 |
| Phase 2 | 5 | Withdrawn 5 |
Follow Respiratory Hypersensitivity: new trials by email Literature Review of Respiratory Hypersensitivity trials Research Report on Respiratory Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Formoterol 6 mcg/Fluticasone 125 mcg by Eurofarma Laboratórios S.A. Versus Alenia® 6 mcg/200 mcg in Patients With Asthma (FORASMA) N0783, Alenia® (Formoterol 6 mcg / Budesonide 200 mcg) - Moderate Asthma | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-10-01 | 2026-10-23 | |
| Parallel, Double-dummy, Superiority Study Levocetirizine/Pseudoephedrine x Zina for Allergic Rhinitis in Brazil Administration of investigation of Eurofarma drug, Administration of Comparator - Allergic Rhinitis | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2026-03-01 | 2025-12-18 | |
| Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray Dupilumab - Allergic Fungal Rhinosinusitis (AFRS), Chronic Rhinosinusitis (CRS) | Phase 3 | Withdrawn | National Institute on Deafness and Other Communication Disorders (NIDCD) | 2024-07-17 | 2024-07-25 | |
| Terbutaline Sulfate in Adults With Asthma Terbutaline - Asthma | Phase 2 / Phase 3 | Withdrawn | Kanecia Obie Zimmerman | 2023-07-07 | 2026-01-22 | |
| Efficacy and Safety of Magnólia Nasal Gel in the Treatment of Allergic Rhinitis MAGNÓLIA NASAL GEL, MOMETASONE FUROATE - Allergic Rhinitis | Phase 3 | Withdrawn | EMS | 2022-08-01 | 2022-08-05 | |
| Pharmacodynamic Bioequivalence Study of Albuterol Sulfate Inhalation Aerosol, 0.09 mg Albuterol Base/ Inhalation Methacholine Chloride, Albuterol Sulfate HFA 0.09 mg (Reference), Albuterol Sulfate HFA 0.18 mg (Reference) - Bronchial Asthma | Phase 3 | Withdrawn | Aurobindo Pharma Ltd | 2022-04-01 | 2022-05-20 | |
| Investigating the Effects of QVM149 on MRI Ventilation Defects QVM149, High Dose Dual Therapy (ICS/LABA) - Asthma | Phase 3 | Withdrawn | Dr. Grace Parraga | 2021-12-01 | 2021-12-14 | |
| The Role of Ketamine as an Adjuvant Therapy for Children With Acute Status Asthmaticus Ketamine - Status Asthmaticus | Phase 3 | Withdrawn | Augusta University | 2020-01-01 | 2024-02-06 | |
| Clinical Study, Non Inferiority Between Noex® 50µg Versus Busonid® 50µg in Treatment of Allergic Rhinitis Budesonid 50mcg (Noex), Budesonid 50mcg (Busonid) - Rhinitis, Allergic, Perennial | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2019-10-08 | 2019-10-09 | |
| Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis CPM, Placebo - Allergic Rhinitis, Nasal Congestion | Phase 2 / Phase 3 | Withdrawn | Larkin Community Hospital | 2019-07-30 | 2023-10-16 | |
| Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis EMS Mometasone gel, Mometasone spray nasal - Allergic Rhinitis | Phase 3 | Withdrawn | EMS | 2019-05-01 | 2020-11-04 | |
| Efficacy and Safety of the Mometasone Nasal Gel in the Treatment of Persistent Allergic Rhinitis EMS Mometasone gel, Mometasone spray nasal - Allergic Rhinitis | Phase 3 | Withdrawn | EMS | 2019-05-01 | 2020-11-04 | |
| Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Persistent Asthma Beclomethasone 800 µg per day, Placebo, Beclomethasone 400 µg per day - Asthma | Phase 3 | Withdrawn | Adamis Pharmaceuticals Corporation | 2019-02-01 | 2019-07-17 | |
| Beclomethasone Dipropionate HFA in Adult and Adolescent Subjects With Mild to Moderate Persistent Asthma Placebo, 400 µg per day Beclomethasone, 200 µg per day Beclomethasone - Asthma | Phase 3 | Withdrawn | Adamis Pharmaceuticals Corporation | 2019-02-01 | 2019-07-17 | |
| Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol (FP/SAL) Plus Tiotropium (TIO) in Inadequately Controlled Asthma FF/UMEC/VI, FP/SAL, Tiotropium - Asthma | Phase 3 | Withdrawn | GlaxoSmithKline | 2019-01-18 | 2019-03-25 | |
| Clinical Study, Non Inferiority Between Noex® 32µg Versus Budecort Aqua® 32µg in Treatment of Alergic Rhinitis Budesonide - Rhinitis, Allergic, Perennial | Phase 3 | Withdrawn | Eurofarma Laboratorios S.A. | 2016-06-01 | 2019-10-09 | |
| A Single-Arm Study to Evaluate Administration of Lebrikizumab by Participants or Caregivers in the Home Setting Lebrikizumab, Prefilled Syringes - Asthma | Phase 3 | Withdrawn | Hoffmann-La Roche | 2015-09-29 | 2018-04-25 | |
| Randomized, Placebo-controlled Study Comparing Efficacy of Fluticasone/Salmeterol Combination to Advair in Asthmatics Fluticasone propionate 100 mcg / salmeterol 50 mcg, Generic fluticasone propionate 100 mcg / salmeterol 50 mcg, Placebo - Asthma | Phase 3 | Withdrawn | Actavis Inc. | 2015-09-01 | 2019-07-05 | |
| Study of Efficacy and Safety of NVA237 in Patients With Poorly Controlled Asthma NVA237, Placebo to NVA237, salbutamol/ albuterol - Asthma | Phase 3 | Withdrawn | Novartis Pharmaceuticals | 2015-03-01 | 2015-04-13 | |
| Efficacy and Safety of Mometasone Furoate for Persistent Asthma Previously Treated With Low-Dose Inhaled Glucocorticosteroids (ICS) (Study P06115) SCH 32088 mometasone furoate (MF) metered-dose inhaler, Placebo metered-dose inhaler BID - Asthma | Phase 3 | Withdrawn | Organon and Co | 2012-06-01 | 2022-02-16 |
Showing 20 of 32. Sign in to see all of them.
Asthma (21) · Rhinitis, Allergic (7) · Asthma, Exercise-Induced (2) · Rhinitis, Allergic, Perennial (2) · Allergic Fungal Sinusitis (1) · Emphysema (1) · Heart Failure (1) · Hypersensitivity (1) · Lung Diseases (1) · Motor Activity (1) · Nasal Obstruction (1) · Nasal Polyps (1) · Pulmonary Disease, Chronic Obstructive (1) · Respiratory Distress Syndrome (1) · Respiratory Insufficiency (1)
Hypersensitivity, Immediate (32) · Immune System Diseases (32) · Respiratory Tract Diseases (32) · Hypersensitivity (31) · Bronchial Diseases (22) · Lung Diseases, Obstructive (21) · Lung Diseases (20) · Nose Diseases (11) · Otorhinolaryngologic Diseases (11) · Rhinitis (10) · Rhinitis, Allergic (3) · Exercise-Induced Allergies (2) · Pathological Conditions, Signs and Symptoms (2) · Respiration Disorders (2)
Albuterol (3) · Mometasone Furoate (3) · Beclomethasone (2) · Budesonide (2) · Fluticasone (2) · Formoterol Fumarate (2) · Metered Dose Inhalers (2) · montelukast (2) · Acetaminophen (1) · Adrenal Cortex Hormones (1) · Adrenergic beta-Agonists (1) · Chlorpheniramine (1) · Colchicine (1) · Fluticasone-Salmeterol Drug Combination (1) · Glycopyrrolate (1)
Eurofarma Laboratorios S.A. (4) · EMS (3) · Adamis Pharmaceuticals Corporation (2) · GlaxoSmithKline (2) · Organon and Co (2) · Actavis Inc. (1) · Alung Technologies (1) · Augusta University (1) · Aurobindo Pharma Ltd (1) · Azidus Brasil (1) · Children's Hospital Medical Center, Cincinnati (1) · Dr. Grace Parraga (1) · Hoffmann-La Roche (1) · Kanecia Obie Zimmerman (1) · Larkin Community Hospital (1)
United States (8) · Brazil (4) · Canada (1) · Germany (1) · United Kingdom (1)
Dennis Carlo (2) · Beverley Patterson, PhD (1) · Elliot Israel (1) · Fu-Tong Liu, MD, PhD (1) · Grace E Parraga, PhD (1) · Hengameh Raissy, Pharm.D. (1) · Homer A. Boushey (1) · Jason Lang, MD (1) · Joseph Marialouis, MD (1) · Joshua Levy, M.D. (1) · Keith Cross, MD (1) · Laurie Johnson, MD (1) · Marcos A Sanchez-Gonzalez (1)
2017 (1), U10HL051823 (1), U10HL051831 (1), U10HL051834 (1), U10HL051843 (1), U10HL051845 (1), U10HL056443 (1), U10HL074073 (1), U10HL074204 (1), U10HL074206 (1), U10HL074208 (1), U10HL074212 (1), U10HL074218 (1), U10HL074225 (1), U10HL074227 (1)